Korean aesthetic device company reported on Wednesday the receipt of the US Food and Drug Administration's 510 (K) clearance to market WONTECH SANDRO DUAL laser device across the global markets, including the US and Europe.
Recently, the SANDRO DUAL was launched in Korea Nd:YAG & Alexandrite based lasers mounted on one device.
According to the company, the SANDRO DUAL can be implemented in the hybrid mode in a short time difference between two wavelengths of 755nm and 1064nm. The energy is accurately delivered to a specific area to deliver an effective and quick treatment in hair removal as well as whitening without damaging surrounding tissue.
In addition, the the SANDRO DUAL's SCS (Skin Cooling Spray) cooling system minimizes patient discomfort from pain, swelling and redness.
European Commission approves Sobi's Aspaveli for rare kidney diseases
US FDA accepts IND application for AskBio's AB-1009
EspeRare and n-Lorem partner to expand European access to ASO therapies for rare genetic diseases
Bionpharma and STEERLife's Etravirine tablets approved by US FDA
Kestra partners with Biobeat to add cuffless blood pressure monitoring to wearable defibrillator
argenx secures FDA priority review for VYVGART in seronegative myasthenia gravis
Abbisko Therapeutics reports US FDA acceptance of pimicotinib NDA
Formosa Pharmaceuticals licenses APP13007 ophthalmic therapy to Samil for South Korea
Summit Therapeutics submits FDA application for ivonescimab in EGFR-mutated lung cancer
Sanofi's Teizeild approved in EU to delay stage 3 type 1 diabetes
Renalytix expands US clinical footprint with three kidneyintelX.dkd integrations
EQT Life Sciences exits Vivasure Medical in EUR185m sale to Haemonetics
FDA accepts NDA resubmission for Camurus' acromegaly drug Oclaiz